Asenapine for bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 3007-3017

  Scheidemantel, Thomas ^a   Korobkova, Irina ^b   Rej, Soham ^c,d   Sajatovic, Martha ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Asenapine; Bipolar; Depressive features; Manic episode; Mixed episode; Safety; tolerability

Indexed keywords

ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HEMOGLOBIN A1C; LIPID; LITHIUM SALT; OLANZAPINE; PLACEBO; TETRACYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AKATHISIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CARDIOVASCULAR DISEASE; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; HUMAN; HYPERPROLACTINEMIA; LIPID BLOOD LEVEL; MANIA; MONOTHERAPY; MOUTH DISEASE; NAUSEA; PARKINSONISM; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

EID: 84949563452     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S78043     Document Type: Review

References (47)

1. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15(1): 1-44.
2. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1575-1586.
3. Ratnasingham S, Cairney J, Manson H, Rehm J, Lin E, Kurdyak P. The burden of mental illness and addiction in Ontario. Can J Psychiatry. 2013; 58(9): 529-537.
4. Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012; 25(1): 20-25.
5. Forte A, Baldessarini RJ, Tondo L, Vazquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015; 178: 71-78.
6. Gildengers A, Tatsuoka C, Bialko C, et al. Correlates of disability in depressed older adults with bipolar disorder. Cut Edge Psychiatry Pract. 2013; 2013(1): 332-338.
7. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010; 375(9712): 385-395.
8. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 160-168.
9. Parikh SV, Zaretsky A, Beaulieu S, et al. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. J Clin Psychiatry. 2012; 73(6): 803-810.
10. Jones SH, Smith G, Mulligan LD, et al. Recovery-focused cognitive-behavioural therapy for recent-onset bipolar disorder: randomised controlled pilot trial. Br J Psychiatry. 2015; 206(1): 58-66.
11. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005; 62(9): 996-1004.
12. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr Serv. 2006; 57(5): 660-665.
13. Forest Pharmaceuticals I. Highlights of Prescribing Information, Saphris (asenapine) sublingual tablets; 2009. Available from: http://pi. actavis. com/data_stream. asp?product_group=1908&p=pi&language=E. Accessed November 12, 2015.
14. Drug Approval Package, Saphris (Asenapine) Tablet [webpage on the Internet]. MD, USA: US Food and Drug Administration; 2009. Available from: http://www. accessdata. fda. gov/drugsatfda_docs/nda/2009/022117s000TOC. cfm. Accessed June 7, 2015.
15. Gerrits M, de Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos. 2010; 31(5-6): 351-357.
16. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009; 63(12): 1762-1784.
17. Jardemark K, Marcus MM, Shahid M, Svensson TH. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse. 2010; 64(11): 870-874.
18. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7): 673-686.
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010; 122(1-2): 27-38.
20. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012; 32(1): 46-55.
21. Baruch Y, Tadger S, Plopski I, Barak Y. Asenapine for elderly bipolar manic patients. J Affect Disord. 2013; 145(1): 130-132.
22. Sajatovic M, Dines P, Fuentes-Casiano E, et al. Asenapine in the treatment of older adults with bipolar disorder. Int Journal Geriatr Psychiatry. 2015; 30(7): 710-719.
23. Grande I, Hidalgo-Mazzei D, Nieto E, et al. Asenapine prescribing patterns in the treatment of manic in-and outpatients: Results from the MANACOR study. Eur Psychiatry. 2015; 30(4): 528-534.
24. Cazorla P, Zhao J, Mackle M, Szegedi A. Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis. Neuropsychiatr Dis Treat. 2013; 9: 409-413.
25. Szegedi A, Zhao J, McIntyre RS. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program. J Affect Disord. 2013; 150(3): 745-752.
26. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013; 145(1): 62-69.
27. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. Journal Clin Psychiatry. 2015; 76(6): 728-734.
28. McIntyre RS, Cohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013; 150(2): 378-383.
29. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011; 11: 101.
30. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010; 126(3): 358-365.
31. Merck Sharpe and Dohme Corporation. Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder. Available from: https://clinicaltrials. gov/ct2/show/NCT01244815?term=asenapine+pediatric+bipolar&rank=1. NLM identifier: NCT01244815. Accessed July 16, 2015.
32. Merck Sharpe and Dohme Corporation. Extension Study of Asenapine (NCT01244815) for Pediatric Bipolar Disorder. Available from: https://clinicaltrials. gov/ct2/show/NCT01349907?term=asenapine+pediatric+bipolar&rank=2. NLM identifier: NCT01349907. Accessed July 16, 2015.
33. U. S. Food and Drug Administration [database on the Internet]. New Pediatric Labeling Information Database-Detail: Asenapine. Available from: http://www. accessdata. fda. gov/scripts/sda/sdDetailNavigation. cfm?sd=labelingdatabase&id=14F7A847BCD30979E053564DA8C00FF5&rownum=15. Accessed July 16, 2015.
34. Young AH, Altamura AC, Gonzalez-Pinto AM, Millet B, Wiedemann K. Use of asenapine in clinical practice for the management of bipolar mania. J Psychopharmacol. 2013; 27(4 Suppl): 3-13.
35. Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat. 2013; 9: 1145-1157.
36. Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014; 13(6): 803-830.
37. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry. 2006; 67(7): 1034-1041.
38. Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013; 170(3): 265-274.
39. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2011; 17(6): 645-648.
40. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014; 75(3): 238-245.
41. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009; 11(8): 815-826.
42. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009; 49(11): 1297-1308.
43. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014; 28(5): 421-453.
44. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009; 23(1): 65-73.
45. Caresano C, Di Sciascio G, Fagiolini A, et al. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context. Adv Ther. 2014; 31(8): 873-890.
46. Sawyer L, Azorin JM, Chang S, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. J Med Econ. 2014; 17(7): 508-519.
47. Michalak EE, Guiraud-Diawara A, Sapin C. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials. Curr Med Res Opin. 2014; 30(4): 711-718.